<DOC>
	<DOCNO>NCT02316470</DOCNO>
	<brief_summary>Phase 2 , randomize , observer-blind , placebo-controlled , multi-centric study include 4 parallel study group . 500 Subjects ( thereof , 250 age 50 - 64 year 250 age 65 year old ) randomize ( 3:3:3:1 ) ratio receive either VLA84 75 µg w/o ( without ) Alum , VLA84 200 µg w/o Alum , VLA84 200 µg w/ ( ) Alum ( 150 subject ) , placebo ( 50 subject ) , i.m . ( intramuscular ) vaccination alternate arm , Days 0 , 7 28</brief_summary>
	<brief_title>Dose-Confirmation , Immunogenicity Safety Study Clostridium Difficile Vaccine Candidate VLA84 Healthy Adults Aged 50 Years Older . Phase II Study</brief_title>
	<detailed_description>This randomize , control , observer-blind Phase 2 study aim confirm optimal dose formulation VLA84 healthy adult age ≥ 50 year age . The study enrol two age stratum , subject age 50 - 64 year subject age 65 year old , 1:1 ratio . 500 subject ( thereof , 250 age 50 - 64 year 250 age 65 year old ) randomize 3:3:3:1 ratio receive either VLA84 75 µg w/o Alum , VLA84 200 µg w/o Alum , VLA84 200 µg w/ Alum ( 150 subject ) , placebo ( 50 subject ) . Vaccinations consist two i.m . injection administer close proximity deltoid region Day 0 , 7 28 , start non-dominant arm alternating arm vaccination day . The study investigate immunogenicity safety VLA84 six month last vaccination , i.e . 210 day per subject . The study include eight outpatient visit day 0 , 7 , 14 , 28 , 35 , 56 , 120 210 . Serum collect assess humoral immunity day 0 , 7 , 14 , 28 , 35 , 56 , 120 210 . The study OBSERVER blind . This mean pre-defined study staff unblinded , e.g. , staff responsible IMP accountability , preparation administration , monitor responsible IMP accountability , safety staff case safety reason . All person involve study conduct remain blind .</detailed_description>
	<criteria>Subjects age ≥50 year good general health , include subject pharmacologically control condition like hypercholesterolemia , hypertension , type 2 diabetes mellitus . Informed consent form sign dated Subjects confirm suspect prior Clostridium difficile infection episode Previous vaccination Clostridium difficile ( investigational ) vaccine receipt ( investigational ) monoclonal antibody Clostridium difficile toxin Use investigational nonregistered medicinal product within 30 day prior VLA84 vaccination Visit 1 ( Day 0 ) throughout entire study period . Active passive vaccination four week first vaccination Visit 1 entire study period , except influenza ( seasonal pandemic ) pneumococcal vaccine may administer outside 7days interval trial vaccination Subject pregnant , lactating , childbearing potential ( consider nonchildbearing potential , female must postmenopausal least 1 year surgically sterile ) Known thrombocytopenia , bleed disorder , receipt anticoagulant 3 week precede inclusion Visit 4 ( Day28 ) , contraindicate i.m . vaccination judge investigator Clinically relevant renal , hepatic , cardiac , pulmonary central nervous disorder , judge investigator . Subjects hypercholesterolemia , hypertension , type 2 diabetes mellitus require medication allow disease adequately control Receipt blood bloodderived product past 3 month anticipation product study period Known congenital , hereditary acquire immunodeficiency , include know infection human immunodeficiency virus ( HIV ) , administration chronic ( define longer 14 day ) immunosuppressant immunemodifying drug within 30 day prior VLA84 vaccination Visit 1 ( Day 0 ) study Visit 5 ( Day 35 ) . For corticosteroid mean prednisone equivalent ≥ 0.05 mg/kg/day ; topical inhale steroid allow . Periodic steroid injection , e.g. , intraarticular , allow within 30 day prior first VLA84 vaccination Visit 1 ( Day 0 ) Visit 5 ( Day 35 ) History autoimmune disease , include Type I Diabetes mellitus . Subjects vitiligo thyroid disease take thyroid hormone replacement exclude Any malignancy past 5 year . If treatment cancer successfully complete 5 year ago malignancy consider cure , subject may enrol Known hypersensitivity allergic reaction one component vaccine Inability unwillingness provide inform consent Persons commit institution ( virtue order issue either judicial administrative authority ) Persons dependent relationship sponsor , investigator study team member , study center . Dependent relationship include close relative household member ( i.e. , child , partner/spouse , sibling , parent ) well employee investigator study center personnel</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Clostridium difficile</keyword>
	<keyword>Valneva</keyword>
	<keyword>Phase 2</keyword>
	<keyword>Healthy adult</keyword>
</DOC>